AbbVie Inc.
$289.24
+3.25 · +1.14% today
Market open · updated 12:44:26 PM ET
- High
- $288.54 11:00 AM
- Low
- $283.10 7:30 AM
Against the S&P 500 Price change through Oct 27, 2026
ABBV+25.36%
S&P 500+12.87%
ABBV+25.62%
S&P 500+12.32%
ABBV+106.18%
S&P 500+87.41%
ABBV+164.24%
S&P 500+69.55%
Key numbers
- Previous close
- $285.99
- Open
- $291.00
- Day's range
- $288.75 – $292.58
- 52-week range
- $190.75 – $292.58
- Volume
- 1.5 million
- Average volume
- 5.9 million
- Market value
- $511.1 billion
- Price to earnings
- 80.8last 12 months
- Earnings per share
- $3.57last 12 months
- Beta
- 0.28moves less than the market
- Dividend
- $6.92 a year · 2.41%
- 50-day average
- $268.13
- 200-day average
- $236.38
Friday, Oct 30, 2026, before the open.
Analyst price targets and the full financials are in the terminal.
Who AbbVie buys from and competes with From our value chain
AbbVie in the news
- HeadlineThe Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18PRNewsWire · October 28, 2026 at 8:00 AM ET
- HeadlineRetire on Dividends: 5 High-Yield Stocks Boomers Are Buying and Holding Forever24/7 Wall Street · October 28, 2026 at 7:12 AM ET
- Headline4 Arthritis Drug Stocks Investors Should Monitor for Growth PotentialZacks Investment Research · October 27, 2026 at 1:23 PM ET
- HeadlineBuy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 EarningsZacks Investment Research · October 27, 2026 at 12:36 PM ET
- HeadlineAbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy)Seeking Alpha · October 27, 2026 at 12:31 PM ET
- HeadlineWhat's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?Zacks Investment Research · October 27, 2026 at 11:50 AM ET
- HeadlineAllergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)PRNewsWire · October 27, 2026 at 8:30 AM ET
- HeadlineAbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple MyelomaPRNewsWire · October 27, 2026 at 8:00 AM ET
Earnings
Next report: Friday, Oct 30, 2026, before the open.
Congress trades in ABBV
2 purchases and 6 sales in the latest 8 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Ro KhannaHouse · D-California | Sale | $15,001 - $50,000 | Sep 4, 2026 | Oct 9, 2026 |
| Pete SessionsHouse · R-Texas | Sale | $15,001 - $50,000 | Sep 14, 2026 | Sep 21, 2026 |
| Ro KhannaHouse · D-California | Purchase | $15,001 - $50,000 | May 1, 2026 | Jun 11, 2026 |
| Josh GottheimerHouse · D-New Jersey | Sale | $1,001 - $15,000 | May 5, 2026 | Jun 4, 2026 |
| Julie JohnsonHouse · D-Texas | Sale | $1,001 - $15,000 | Dec 18, 2025 | Jan 16, 2026 |
| Julia LetlowHouse · R-Louisiana | Sale | $1,001 - $15,000 | Dec 8, 2025 | Jan 14, 2026 |
| Julia LetlowHouse · R-Louisiana | Purchase | $1,001 - $15,000 | Apr 28, 2025 | Jan 14, 2026 |
| Julia LetlowHouse · R-Louisiana | Sale | $1,001 - $15,000 | Jan 24, 2025 | Jan 14, 2026 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About AbbVie
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 57,000
- Headquarters
- North Chicago, Illinois
- Website
- abbvie.com
- Listed
- Jan 2, 2013
More drug manufacturers - general stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.